5 completed, 1 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Porphyria Cutanea Tarda: new trials by email Literature Review of Porphyria Cutanea Tarda trials Research Report on Porphyria Cutanea Tarda
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Harvoni Treatment Porphyria Cutanea Tarda Harvoni - Porphyria Cutanea Tarda, Hepatitis C | Phase 2 | Completed | Wake Forest University Health Sciences | 23 | 2017-09-06 | 2023-07-03 |
| Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda Exjade - Porphyria Cutanea Tarda | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 45 | 2011-01-01 | 2011-01-27 |
| Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda Deferasirox - Porphyria Cutanea Tarda | Phase 3 | Completed | University of Texas Southwestern Medical Center | 10 | 2008-01-01 | 2014-02-10 |
| Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda Hydroxychloroquine, Phlebotomy - Porphyria Cutanea Tarda | Phase 2 | Completed | The University of Texas Medical Branch, Galveston | 48 | 2006-03-21 | 2023-02-17 |
| Study of the Pathogenesis of Porphyria Cutanea Tarda Porphyria Cutanea Tarda | Completed | National Center for Research Resources (NCRR) | 120 | 2000-11-01 | 2005-06-24 | |
| Risk Factors of Porphyria Cutanea Tarda (PCT) Porphyria Cutanea Tarda | Completed | University Hospital, Strasbourg, France | 280 | 1999-05-01 | 2005-09-21 |
Hepatitis C (2) · Porphyrias (2) · Rare Diseases (2) · Hemochromatosis (1) · Metabolism, Inborn Errors (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Digestive System Diseases (6) · Genetic Diseases, Inborn (6) · Liver Diseases (6) · Metabolic Diseases (6) · Nutritional and Metabolic Diseases (6) · Porphyrias, Hepatic (6) · Skin Diseases (6) · Skin Diseases, Genetic (6) · Skin and Connective Tissue Diseases (6) · Porphyrias (4) · Blood-Borne Infections (2) · Communicable Diseases (2) · Disease Attributes (2) · Flaviviridae Infections (2)
Deferasirox (2) · Hydroxychloroquine (1) · Phlebotomy (1) · Sofosbuvir (1) · ledipasvir (1) · ledipasvir, sofosbuvir drug combination (1)
Assistance Publique - Hôpitaux de Paris (1) · National Center for Research Resources (NCRR) (1) · The University of Texas Medical Branch, Galveston (1) · University Hospital, Strasbourg, France (1) · University of Texas Southwestern Medical Center (1) · Wake Forest University Health Sciences (1)
United States (4) · France (1)
Amit Pandya, M.D. (1) · Bernard Cribier, MD (1) · Deybach Jean-Charles, Professor (1) · Herbert L Bonkovsky, MD (1) · J.P Lacour, MD (1) · Karl E Anderson, MD (1) · Karl Elmo Anderson (1) · M. Bagot, MD (1) · O. Chosidow, MD (1) · Sean Rudnick, MD (1)
PMID 20226990, PMID 22911183, PMID 22985607, PMID 36811718
U54DK083909 (1)